Cardiac Myosin Inhibitors
2 drugsAbout Cardiac Myosin
Cardiac myosin is the motor protein responsible for muscle contraction in the heart, playing a crucial role in the heart's ability to pump blood effectively. It is a key player in cardiovascular health.
Cardiac myosin has emerged as a therapeutic target, evidenced by the FDA approval of two drugs. Currently, there is no genetic evidence data available linking cardiac myosin to specific diseases.
Two small molecule drugs, MYQORZO and CAMZYOS, target cardiac myosin. These drugs are developed by CYTOKINETICS and Bristol-Myers Squibb, respectively, and address indications in the 'other' therapeutic area.
Top Cardiac Myosin Drugs
The competitive landscape consists of two companies, CYTOKINETICS and Bristol-Myers Squibb.
Low market concentration suggests relatively low barriers to entry for new competitors.
Cardiac Myosin Drug Modality Landscape
Modalities
Routes of Administration
Cardiac Myosin is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies or peptides.
Cardiac Myosin Clinical Trials 28 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cardiac Myosin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 | 100% |
| Phase 2 | 6 | 4 | 0 | 2 | 100% |
| Phase 3 | 10 | 7 | 1 | 2 | 88% |
| Phase 4 | 5 | 0 | 0 | 5 | - |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Cardiac Myosin drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Cardiac Myosin. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Cardiac Myosin Drug Approval Timeline (2022 - 2025)
The first drug targeting cardiac myosin was approved in 2022, with the most recent approval in 2025.
Recent approvals indicate a growing interest in cardiac myosin, but it is too early to assess saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cardiac Myosin. A trial counts if an approved drug acting on Cardiac Myosin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.